Compare Natera Inc. Common Stock (NTRA) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs VNET Group Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while VNET Group Inc trades at $4.5 (market cap $1.49B). The key difference: Natera Inc. Common Stock is far larger — about 38.3× VNET Group Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and VNET Group Inc for 16 Days on average.
| NTRA | VNET | |
|---|---|---|
Market Cap | $57.03B | $1.49B |
Volume | 1,131,157 | 3,619,133 |
Sector | Health | Technology |
52-Week High | $425.64 | $14.03 |
52-Week Low | $179.42 | $4.49 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $56.18B | $5.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VNET trades at $5.26, down 1.13% today, and has hit new 52-week lows recently. The technical outlook is bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Recent news includes a strategic investment closing and a cooperation agreement with CATL, providing some positive catalysts amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst sentiment is moderately positive with a 'Buy' consensus. Key risks include balance sheet strain and competitive pressures in the data center market. Investment opportunity hinges on execution of growth initiatives and improvement in profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
